Sign In
Buy ASLN
$0.600
+0 (+0%)
At Close: Oct 17, 2024
SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovati
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
07:00am, Thursday, 01'st Jun 2023
SAN MATEO, Calif. and SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
11:27am, Thursday, 27'th Apr 2023
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
11:26am, Wednesday, 05'th Apr 2023
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.
Bears are Losing Control Over ASLAN Pharmaceuticals Ltd. (ASLN), Here's Why It's a 'Buy' Now
11:25am, Thursday, 09'th Mar 2023
ASLAN Pharmaceuticals Ltd. (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
11:18am, Thursday, 02'nd Mar 2023
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
07:00am, Friday, 16'th Dec 2022
SAN MATEO, Calif. and SINGAPORE, Dec. 16, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments
ASLAN Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Friday, 02'nd Sep 2022
MENLO PARK, Calif. and SINGAPORE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatment
ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022
07:00am, Wednesday, 06'th Apr 2022
MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment
ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis
12:20pm, Friday, 21'st Jan 2022
ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis.
ASLAN Pharma Kickstarts Mid-Stage Atopic Dermatitis Trial, Data Expected In 2023
06:36am, Friday, 21'st Jan 2022
ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with moderate-to-severe atopic dermatitis (AD). Ebla
Aslan Pharmaceuticals begins phase2b study of ASLAN004 for eczema
09:28pm, Thursday, 20'th Jan 2022 Seeking Alpha
Aslan Pharmaceuticals (ASLN) screened the first patient in its phase 2b dose-ranging study of eblasakimab in adults with moderate-to-severe atopic dermatitis ((AD)), also
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022
12:00pm, Thursday, 06'th Jan 2022 Benzinga
MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN ), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022. An Full story available on Benzinga.com
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022
07:00am, Thursday, 06'th Jan 2022
MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatment
ASLAN Pharmaceuticals Ltd - ADR Shares Close in on 52-Week Low - Market Mover
05:56am, Friday, 31'st Dec 2021 Kwhen Finance
ASLAN Pharmaceuticals Ltd - ADR (ASLN) shares closed today at 0.9% above its 52 week low of $1.10, giving the company a market cap of $42M. The stock is currently down 38.8% year-to-date, down 38.8% over the past 12 months, and down 80.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Trading Activity Trading volume this week was 2.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 26.3% The company's stock price performance over the past 12 months lags the peer average by 22.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
